| ULMEGZI CELGENE CORPORATION
2163576 02 Feb 2022 | on 12 Feb 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; pharmaceutical preparations for human use for the treatment and prevention of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics, cytokine inhibitory drugs; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents; pharmaceutical preparations for human use that modulate the immune system; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for use in immunotherapies; pharmaceutical preparations for use in T-cell immunotherapy; pharmaceutical preparations for use in cell therapy; pharmaceutical preparations for human use namely T-cells for medical purposes; pharmaceutical preparations for human use namely diagnostic kits consisting primarily of cells for medical laboratory use; Pharmaceutical preparations for human use for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use namely antivirals for treatment and prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; pharmaceutical preparations for human use namely monoclonal antibodies. | | | AUMEGZI CELGENE CORPORATION
2163086 31 Jan 2022 | on 29 Dec 2023 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical and biological preparations for human use | | | JEMEGZI CELGENE CORPORATION
2163093 31 Jan 2022 | on 28 Mar 2024 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for oncology | | | JUNGZI KIRANDEEP KAUR
2124547 02 Aug 2021 | on 11 Jan 2024 | Class 021 Class 021 Houseware and Glass Products Lint rollers | | | XINGZI JUNCHENG LIU
2081034 29 Jan 2021 | on 21 Mar 2024 | Class 021 Class 021 Houseware and Glass Products Cosmetic brushes; Cosmetic spatulas; Droppers for cosmetic purposes; Eyebrow brushes; Eyelash brushes; Eyeliner brushes; Fitted vanity cases; Make-up brushes; Make-up sponges; Perfume bottles sold empty; | | | PANGZI CHONGQING PANGZI TIANJIAO RONGXING FOOD CO.LTD
2073466 15 Oct 2020 | on 28 Sep 2022 | Class 030 Class 030 Staple Food Products Vinegar; soy sauce [soya sauce]; sugar; seasonings; starch for food; chili seasonings. | | | AVLAGZI BRISTOL-MYERS SQUIBB COMPANY (A DELAWARE CORPORATION)
1877972 17 Jan 2018 | on 28 Feb 2020 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, heart failure, thrombosis, stroke, cancer, respiratory diseases, auto-immune diseases, rheumatoid arthritis, lupus, inflammatory bowel disease, solid organ transplant rejection, hepatitis, fibrosis; pharmaceutical preparations for human use, namely, immunotherapies for the treatment of cancer; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, anti-inflammatories, anti-infectives, central nervous system depressants, central nervous system stimulants, anti-psychotics; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for the treatment of cancer, respiratory diseases, auto-immune diseases, and for the prevention and treatment of solid organ transplant rejection; pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; diagnostic pharmaceutical preparations for human use for increasing the heart rate and for use as medical imaging contrast agents. | |